Alkemi Growth Capital Research
Investment Thesis
Alkemi Growth Capital is an India-focused healthcare and wellness growth fund. Its stated mission is to elevate the health and well-being of the Indian consumer while maximizing shareholder returns, framing "Sehat" (well-being) as a fourth basic need alongside food, clothing, and shelter. Alkemi invests exclusively in scalable companies with validated product-market fit, governance-aligned leadership, and a clear pathway to institutional scale. The firm describes its approach as combining sector specialization, high-conviction portfolio construction, and long-term partnership capital designed to accelerate market-leading companies with transformative potential in India's healthcare and wellness ecosystem.
Stage Focus
Alkemi's own branding leans "growth capital," but its actual portfolio activity spans Seed through Series B: participation in a $1.4M pre-Series A round for Jobizo, a $3.8M Pre-Series-A lead in Alphadroid, a ₹18 crore (~$2.2M) led round in MedVital, and participation in QuickClean's ₹50 crore Series A (2025) and later $14M Series B (2026, led by Stakeboat Capital). The firm appears comfortable investing from early growth through later, more capital-intensive rounds within its healthcare/wellness mandate.
Check Size
No explicit check-size range is published on the website. Observed round participation ranges from roughly $1.4M (Jobizo pre-Series A) up to co-investing in $14M+ Series B rounds (QuickClean), suggesting a working check size in the low single-digit millions of dollars per investment, sized up for follow-ons in winners.
Lead Tendency
Mixed. Alkemi is credited as lead investor in several rounds (Alphadroid's Pre-Series-A, MedVital's ₹18 crore round, and earlier Jobizo and QuickClean rounds), but also appears as a participating/co-investor in others led by different firms (QuickClean's 2026 Series B led by Stakeboat Capital; ZeroHarm Sciences' ₹65 crore round alongside Kotak Life Sciences Fund).
Recent Activity
Alkemi has been active through 2025 and 2026: leading a $3.8M Pre-Series-A in robotics startup Alphadroid (May 2026), leading a ₹18 crore round in MedVital (May 2026), backing Chosen's $5M raise for its science-led skincare business (May 2026), co-investing in ZeroHarm Sciences' ₹65 crore round with Kotak Life Sciences Fund (Feb 2026), participating in QuickClean's $14M Series B (Jul 2026), and exiting its position in PeeSafe (Jan 2026). In December 2025, VCCircle reported Alkemi was weighing a significantly larger third fund. The firm also hosts founder-facing programming, including a Founders' Roundtable on B2B sales to hospitals (Apr 2026) and participation in the ISB Healthcare 4.0 Summit (Feb 2026), plus an internal "Founders' Day" portfolio gathering (Nov 2025).
Portfolio Highlights
The website lists 20+ active portfolio companies (18 identified with live links), all within Indian healthcare, wellness, and adjacent consumer categories: Redcliffe Labs (diagnostics), PeeSafe (hygiene products, now exited), Uncover and Chosen (science-led skincare/dermatology), Docquity (verified doctor network), Medkart (generic-medicine pharmacy chain), Doceree (physician-engagement/health marketing network), Farmley and Slurrp Farm (healthy food brands), Saveo (pharma B2B distribution), Medulance (emergency medical transport tech), DataRPGx, QuickClean (laundry infrastructure, notably for institutional/hospital settings), Jobizo (healthcare blue-collar HRtech), MedVital, ZeroHarm Sciences (safer personal-care/agri inputs), Jagruti Rehab (addiction rehabilitation), and Alphadroid (robotics). The firm reports $350M+ in follow-on capital raised by its portfolio from domestic and global institutions and 5,000+ direct jobs created across portfolio companies.
Team
- Alka Goel, Founder & Managing Partner — Launched Alkemi in 2017 after relocating from New York to Delhi to invest in Indian healthcare startups; frequently cited in press (VCCircle, Venture Capital Journal, Private Equity International) as the firm's founding investor and public face.
- Dr. Mansi Aggarwal, Partner — Co-leads investment activity and founder engagement alongside Goel; interviewed in Express Healthcare's September 2026 issue and regularly appears in portfolio-company funding announcements and founder-facing events.
- Advisory board: Shantanu Mukerji (Managing Director, Gulf Capital), Utsav Baijal (Head, India Private Equity, Bain Capital), Priyanka Aggarwal (Managing Director & Partner, BCG), Rohit Kapoor (CEO, Swiggy Food Marketplace), Pankaj Sahni (Group CEO, Medanta/Global Health Limited), Abhishek Kalra (Former MD, Lehman Brothers), and Vikas Bhadoria (Former Senior Partner, McKinsey & Company).
Decision Process
A small, partnership-led investment team (Goel and Aggarwal are the two named investing partners on the public site) supported by a deep bench of sector advisors from healthcare, private equity, and consulting backgrounds — consistent with a partnership-style decision process rather than a solo-GP or large investment-committee structure.
Founder Preferences
Alkemi's site explicitly seeks "bold and determined founders" building "disruptive, high-performing companies," describing its ideal partners as entrepreneurs "inspired by a vision," with "boldness in their DNA," who "persevere under uncertainty." The firm emphasizes governance-aligned leadership and validated product-market fit as pre-conditions for investment, and positions itself as a hands-on partner post-investment (process institutionalization, revenue-expansion support via its operator/clinical network, capital discipline, follow-on facilitation).
Geographic Focus
Exclusively India-focused, headquartered in New Delhi, targeting the Indian healthcare and wellness consumer market.
ESG
Alkemi publishes an explicit E&S (Environmental & Social) external communication mechanism, stating that E&S risk management is integrated into its investment process and diligence, with a dedicated channel for external stakeholders to raise E&S concerns about the fund or its investments.
Fund Structure (SEBI)
Alkemi manages at least two SEBI-registered Category II AIFs: Alkemi Venture Fund I (SEBI Reg. No. IN/AIF2/18-19/0533) and Alkemi Venture Fund II – Scheme I (SEBI Reg. No. IN/AIF2/21-22/0984), both managed by Alkemi Growth Capital LLP. External sources (IFC project disclosures) indicate Fund II targeted a $75M raise with a first close of approximately $49.7M; total firm AUM is not precisely confirmed across sources (estimates range from ~$34M to Fund II's raise target) and is therefore omitted rather than guessed.